GB201909493D0 - Therapeutic interactions - Google Patents

Therapeutic interactions

Info

Publication number
GB201909493D0
GB201909493D0 GBGB1909493.7A GB201909493A GB201909493D0 GB 201909493 D0 GB201909493 D0 GB 201909493D0 GB 201909493 A GB201909493 A GB 201909493A GB 201909493 D0 GB201909493 D0 GB 201909493D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic interactions
interactions
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1909493.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Priority to GBGB1909493.7A priority Critical patent/GB201909493D0/en
Publication of GB201909493D0 publication Critical patent/GB201909493D0/en
Priority to JP2021577641A priority patent/JP7638915B2/ja
Priority to US17/620,949 priority patent/US20230031369A1/en
Priority to BR112021025256A priority patent/BR112021025256A2/pt
Priority to EP20739286.1A priority patent/EP3989954A1/en
Priority to PCT/EP2020/068422 priority patent/WO2021001380A1/en
Priority to CA3143790A priority patent/CA3143790A1/en
Priority to CN202080048557.6A priority patent/CN114126622A/zh
Priority to AU2020298758A priority patent/AU2020298758A1/en
Priority to KR1020227003213A priority patent/KR20220027203A/ko
Priority to MX2021015292A priority patent/MX2021015292A/es
Priority to IL289338A priority patent/IL289338B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
GBGB1909493.7A 2019-07-01 2019-07-01 Therapeutic interactions Ceased GB201909493D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
MX2021015292A MX2021015292A (es) 2019-07-01 2020-06-30 Interacciones terapeuticas de leucometiltioninio.
EP20739286.1A EP3989954A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium
US17/620,949 US20230031369A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium
BR112021025256A BR112021025256A2 (pt) 2019-07-01 2020-06-30 Interações terapêuticas de leuco metiltionínio
JP2021577641A JP7638915B2 (ja) 2019-07-01 2020-06-30 ロイコメチルチオニニウムの治療上の相互作用
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium
CA3143790A CA3143790A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium
CN202080048557.6A CN114126622A (zh) 2019-07-01 2020-06-30 无色甲基硫堇鎓的治疗相互作用
AU2020298758A AU2020298758A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium
KR1020227003213A KR20220027203A (ko) 2019-07-01 2020-06-30 류코메틸티오니늄의 치료적 상호작용
IL289338A IL289338B1 (en) 2019-07-01 2021-12-23 Therapeutic interactions of leucomethylthioninium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions

Publications (1)

Publication Number Publication Date
GB201909493D0 true GB201909493D0 (en) 2019-08-14

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1909493.7A Ceased GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions

Country Status (12)

Country Link
US (1) US20230031369A1 (https=)
EP (1) EP3989954A1 (https=)
JP (1) JP7638915B2 (https=)
KR (1) KR20220027203A (https=)
CN (1) CN114126622A (https=)
AU (1) AU2020298758A1 (https=)
BR (1) BR112021025256A2 (https=)
CA (1) CA3143790A1 (https=)
GB (1) GB201909493D0 (https=)
IL (1) IL289338B1 (https=)
MX (1) MX2021015292A (https=)
WO (1) WO2021001380A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7073330B2 (ja) 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) * 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille

Also Published As

Publication number Publication date
EP3989954A1 (en) 2022-05-04
MX2021015292A (es) 2022-01-18
KR20220027203A (ko) 2022-03-07
JP7638915B2 (ja) 2025-03-04
IL289338A (en) 2022-02-01
IL289338B1 (en) 2026-03-01
CN114126622A (zh) 2022-03-01
WO2021001380A1 (en) 2021-01-07
JP2022538642A (ja) 2022-09-05
AU2020298758A1 (en) 2022-02-24
BR112021025256A2 (pt) 2022-01-25
US20230031369A1 (en) 2023-02-02
CA3143790A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
SG11202104461XA (en) Therapeutic methods
GB201909190D0 (en) Therapeutic agents
GB201820166D0 (en) Therapeutic agents
GB201909191D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
GB201909194D0 (en) Therapeutic agents
GB201804255D0 (en) Macrophage-based therapy
GB201900702D0 (en) Therapy
GB201902277D0 (en) Therapeutic agents
GB201819853D0 (en) Therapy
IL292502A (en) Therapeutic methods using vadadustat
GB201805816D0 (en) Therapeutic agents
GB201906804D0 (en) Therapeutic agents
GB201909493D0 (en) Therapeutic interactions
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
GB201817385D0 (en) Therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy
GB201913785D0 (en) Therapy
GB201913797D0 (en) Therapy
GB201912524D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)